Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07474519 · ClinicalTrials.gov registry record · Phase 4
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
A Phase 4 study of Non-Muscle Invasive Bladder Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07474519 is a Phase 4 study of Non-Muscle Invasive Bladder Carcinoma that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 40 participants, below the 146-participant average among 3 other Non-Muscle Invasive Bladder Carcinoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07474519, a Phase 4 study of Non-Muscle Invasive Bladder Carcinoma, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase IV trial studies whether there is a relationship between how a patient is positioned while receiving bacillus Calmette Guerin (BCG) within the bladder (intravesical) and how long BCG stays in the bladder (dwell time) to improve the treatment of non-muscle invasive bladder cancer. For the past 40 years, intravesical BCG has been used for the treatment of non-muscle invasive bladder cancer. An important factor for BCG treatment is the dwell time, which is the period of time a patient can hold the BCG medication in the bladder after it has been given. Normally, patients are instructed during intravesical BCG treatment to avoid emptying the bladder for 2 hours after the BCG is given. However, this may be difficult for some patients who may have limited bladder capacity, restricted movement, or severe urinary symptoms. There have been studies outlining the relationship with increased dwell time and how well the treatment works, but studies on the potential impact of patient positioning or activity on the patient's ability to retain the drug are limited. Researchers hope by studying whether there is a relationship between patient positioning during intravesical BCG treatment and dwell time, they may be able to improve how BCG treatment for non-muscle invasive bladder cancer is given, especially for patients with limited bladder capacity, restricted movement, or severe urinary symptoms.
Conditions Studied
Interventions
- OTHER Electronic Health Record Review
- BIOLOGICAL BCG Solution
- PROCEDURE Accelerometry
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07474519
The ClinicalTrials.gov registry entry for NCT07474519 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 146-participant average among 3 other Non-Muscle Invasive Bladder Carcinoma trials with a reported enrollment target (73% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Muscle Invasive Bladder Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Electronic Health Record Review is the first listed.
NCT07474519 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07474519 about?
NCT07474519 is a clinical study titled "Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer". This phase IV trial studies whether there is a relationship between how a patient is positioned while receiving bacillus Calmette Guerin (BCG) within the bladder (intravesical) and how long BCG stays in the bladder (dwell time) to improve the treatment of non-muscle invasive bladder cancer. For the ...
What is the current status of trial NCT07474519?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2026-02-26. Estimated completion is 2027-12-31.
What conditions does trial NCT07474519 study?
This clinical trial studies the following conditions: Non-Muscle Invasive Bladder Carcinoma.
What interventions are being tested in trial NCT07474519?
The interventions under investigation include: Electronic Health Record Review (OTHER), BCG Solution (BIOLOGICAL), Accelerometry (PROCEDURE).
Who is sponsoring clinical trial NCT07474519?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07474519 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Muscle Invasive Bladder Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
RECRUITING · Phase 1
-
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
RECRUITING · Phase 1
-
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.